stock-detail (FBIO)

Oncology Corporate Profile

Company Description

This company does not have any commercial products

This company does not have any pipeline products

Recent News Headlines

4/24/2017 12:17 pm

4/24/2017 12:17 pm

4/24/2017 12:17 pm

4/24/2017 12:17 pm

4/24/2017 06:18 am

4/24/2017 06:18 am

4/24/2017 06:18 am

4/24/2017 06:18 am

Fortress Biotech to Present at BioCentury’s 24th Annual Future Leaders in the Biotech Industry Conference

3/30/2017 12:00 pm

[GlobeNewswire] - NEW YORK, March 30, 2017-- Fortress Biotech, Inc., a biopharmaceutical company dedicated to acquiring, developing and commercializing novel pharmaceutical and biotechnology products, today announced that ...

Checkpoint Therapeutics to Present Preclinical Data at the American Association for Cancer Research Annual Meeting 2017

3/20/2017 12:00 pm

[GlobeNewswire] - NEW YORK, March 20, 2017-- Checkpoint Therapeutics, Inc., a Fortress Biotech company, today announced that preclinical data on its anti-PD-L1 antibody and EGFR inhibitor programs will be presented in poster ...

Fortress Biotech Reports Financial Results for the Fourth Quarter and Full Year Ended December 31, 2016

3/16/2017 08:00 pm

[GlobeNewswire] - NEW YORK, March 16, 2017-- Fortress Biotech, Inc., a biopharmaceutical company dedicated to acquiring, developing and commercializing novel pharmaceutical and biotechnology products, today announced financial ...

Fortress Biotech Forms New Subsidiary, Cyprium Therapeutics, Inc., to Develop Novel Therapies for Menkes Disease and Related Copper Metabolism Disorders

3/14/2017 11:03 am

[GlobeNewswire] - Cyprium, NICHD establish CRADA to advance clinical development of Phase 3 candidate CUTX-101 in Menkes disease, a rare and fatal pediatric disease. Cyprium licenses preclinical AAV-ATP7A gene therapy from ...

Fortress Biotech to Present at the 29th Annual ROTH Conference

3/9/2017 01:00 pm

[GlobeNewswire] - NEW YORK, March 09, 2017-- Fortress Biotech, Inc., a biopharmaceutical company dedicated to acquiring, developing and commercializing novel pharmaceutical and biotechnology products, today announced that ...

Checkpoint Therapeutics Announces Issuance of U.S. Composition of Matter Patent for Lung Cancer Compound CK-101

2/28/2017 01:00 pm

[GlobeNewswire] - NEW YORK, Feb. 28, 2017-- Checkpoint Therapeutics, Inc., a Fortress Biotech company, today announced that the U.S. Patent and Trademark Office has issued a composition of matter patent for CK-101, Checkpoint’ ...